 Andres Henao Martinez
Concepts (503)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chagas Disease | 13 | 2023 | 44 | 7.050 |
Why?
| | Chagas Cardiomyopathy | 7 | 2023 | 24 | 4.280 |
Why?
| | Meningitis, Cryptococcal | 8 | 2024 | 30 | 3.600 |
Why?
| | Cryptococcosis | 6 | 2023 | 27 | 3.360 |
Why?
| | Opportunistic Infections | 4 | 2024 | 46 | 2.570 |
Why?
| | Trypanosoma cruzi | 6 | 2023 | 40 | 2.350 |
Why?
| | Cryptococcus neoformans | 4 | 2024 | 21 | 1.820 |
Why?
| | Invasive Pulmonary Aspergillosis | 2 | 2023 | 7 | 1.670 |
Why?
| | HIV Infections | 10 | 2024 | 2836 | 1.590 |
Why?
| | Travel | 6 | 2021 | 130 | 1.560 |
Why?
| | Strongyloidiasis | 2 | 2024 | 4 | 1.400 |
Why?
| | Cryptococcus | 2 | 2024 | 11 | 1.380 |
Why?
| | Candidemia | 3 | 2025 | 11 | 1.370 |
Why?
| | Immunocompromised Host | 6 | 2024 | 202 | 1.310 |
Why?
| | Anti-Bacterial Agents | 10 | 2025 | 1809 | 1.260 |
Why?
| | Stroke, Lacunar | 2 | 2019 | 4 | 1.240 |
Why?
| | Transients and Migrants | 3 | 2023 | 24 | 1.140 |
Why?
| | Tuberculosis | 2 | 2022 | 279 | 1.140 |
Why?
| | Humans | 109 | 2025 | 137585 | 1.120 |
Why?
| | Hospitalization | 7 | 2024 | 2199 | 1.070 |
Why?
| | Cardiomyopathies | 2 | 2021 | 350 | 1.070 |
Why?
| | Yellow Fever | 3 | 2022 | 8 | 1.050 |
Why?
| | Candida | 3 | 2025 | 38 | 1.020 |
Why?
| | Bacteremia | 5 | 2023 | 214 | 0.980 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2019 | 184 | 0.970 |
Why?
| | Antifungal Agents | 8 | 2023 | 136 | 0.950 |
Why?
| | Glucocorticoids | 3 | 2024 | 594 | 0.950 |
Why?
| | Central Nervous System Neoplasms | 2 | 2018 | 156 | 0.920 |
Why?
| | Adult | 41 | 2025 | 37929 | 0.920 |
Why?
| | Macrolides | 1 | 2025 | 65 | 0.900 |
Why?
| | Parasitemia | 2 | 2015 | 13 | 0.890 |
Why?
| | Pneumocystis | 1 | 2024 | 10 | 0.880 |
Why?
| | Risk Factors | 16 | 2025 | 10388 | 0.870 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2024 | 38 | 0.860 |
Why?
| | Mycoses | 1 | 2024 | 79 | 0.860 |
Why?
| | Pulmonary Aspergillosis | 1 | 2023 | 3 | 0.850 |
Why?
| | Nitroimidazoles | 1 | 2023 | 13 | 0.850 |
Why?
| | Drug Hypersensitivity | 1 | 2025 | 90 | 0.840 |
Why?
| | Myocarditis | 2 | 2016 | 100 | 0.820 |
Why?
| | Anemia, Aplastic | 1 | 2023 | 38 | 0.820 |
Why?
| | Pneumonia, Viral | 7 | 2020 | 373 | 0.810 |
Why?
| | Coronavirus Infections | 7 | 2020 | 364 | 0.810 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2024 | 127 | 0.810 |
Why?
| | Male | 49 | 2025 | 67762 | 0.800 |
Why?
| | Enterobacteriaceae Infections | 2 | 2013 | 43 | 0.780 |
Why?
| | Zoonoses | 2 | 2024 | 33 | 0.780 |
Why?
| | Virus Diseases | 1 | 2024 | 212 | 0.760 |
Why?
| | Osteomyelitis | 2 | 2025 | 132 | 0.740 |
Why?
| | Antigens, Fungal | 2 | 2024 | 28 | 0.730 |
Why?
| | Neglected Diseases | 1 | 2020 | 4 | 0.700 |
Why?
| | Immunotherapy, Adoptive | 1 | 2024 | 327 | 0.700 |
Why?
| | Mycobacterium Infections | 2 | 2018 | 63 | 0.690 |
Why?
| | Hepatitis | 1 | 2020 | 48 | 0.680 |
Why?
| | Middle Aged | 27 | 2025 | 33479 | 0.680 |
Why?
| | Hantavirus Pulmonary Syndrome | 1 | 2020 | 2 | 0.660 |
Why?
| | Heart Aneurysm | 1 | 2019 | 11 | 0.650 |
Why?
| | Massive Hepatic Necrosis | 1 | 2019 | 3 | 0.630 |
Why?
| | Epidemics | 1 | 2020 | 89 | 0.630 |
Why?
| | Aneurysm, False | 1 | 2019 | 48 | 0.620 |
Why?
| | United States | 20 | 2025 | 14841 | 0.620 |
Why?
| | Hepatitis A | 1 | 2019 | 26 | 0.620 |
Why?
| | Neisseria gonorrhoeae | 1 | 2019 | 26 | 0.610 |
Why?
| | Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 3 | 0.610 |
Why?
| | Sarcoma, Myeloid | 1 | 2018 | 4 | 0.610 |
Why?
| | Hematoma, Subdural | 1 | 2018 | 18 | 0.600 |
Why?
| | Female | 39 | 2025 | 73304 | 0.590 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 30 | 0.580 |
Why?
| | Malaria, Falciparum | 1 | 2018 | 27 | 0.570 |
Why?
| | Skin | 3 | 2022 | 752 | 0.570 |
Why?
| | Gonorrhea | 1 | 2019 | 59 | 0.570 |
Why?
| | Chromoblastomycosis | 1 | 2017 | 1 | 0.570 |
Why?
| | Fever | 2 | 2020 | 306 | 0.570 |
Why?
| | Hand Dermatoses | 1 | 2017 | 7 | 0.560 |
Why?
| | Population Groups | 1 | 2018 | 62 | 0.560 |
Why?
| | Renal Insufficiency | 1 | 2020 | 162 | 0.560 |
Why?
| | Delayed Diagnosis | 1 | 2018 | 91 | 0.550 |
Why?
| | Dyspnea | 1 | 2019 | 254 | 0.550 |
Why?
| | Meningioma | 1 | 2018 | 91 | 0.550 |
Why?
| | Medically Uninsured | 1 | 2018 | 130 | 0.550 |
Why?
| | Meningeal Neoplasms | 1 | 2018 | 100 | 0.540 |
Why?
| | Abscess | 1 | 2018 | 75 | 0.540 |
Why?
| | Milk | 1 | 2018 | 124 | 0.530 |
Why?
| | Retrospective Studies | 13 | 2025 | 15657 | 0.530 |
Why?
| | Heart Failure | 2 | 2022 | 2236 | 0.520 |
Why?
| | Latin America | 6 | 2022 | 93 | 0.520 |
Why?
| | Poliomyelitis | 3 | 2022 | 37 | 0.520 |
Why?
| | Pandemics | 10 | 2023 | 1639 | 0.520 |
Why?
| | Prisons | 4 | 2021 | 81 | 0.510 |
Why?
| | Trichuriasis | 1 | 2016 | 4 | 0.510 |
Why?
| | Pregnancy Complications, Parasitic | 1 | 2016 | 9 | 0.510 |
Why?
| | Lymphocytosis | 1 | 2016 | 11 | 0.510 |
Why?
| | Parotid Neoplasms | 1 | 2016 | 16 | 0.500 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2016 | 24 | 0.500 |
Why?
| | Enterobacteriaceae | 2 | 2013 | 40 | 0.500 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2016 | 19 | 0.500 |
Why?
| | Diphyllobothriasis | 1 | 2015 | 2 | 0.490 |
Why?
| | Diphyllobothrium | 1 | 2015 | 2 | 0.490 |
Why?
| | Plasmablastic Lymphoma | 1 | 2015 | 7 | 0.490 |
Why?
| | Colombia | 4 | 2020 | 41 | 0.490 |
Why?
| | Occupational Diseases | 1 | 2017 | 156 | 0.490 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2018 | 213 | 0.480 |
Why?
| | Insect Vectors | 1 | 2015 | 39 | 0.480 |
Why?
| | Gamma Rays | 1 | 2015 | 57 | 0.480 |
Why?
| | Plasma Cells | 1 | 2015 | 71 | 0.470 |
Why?
| | Transplants | 1 | 2015 | 36 | 0.470 |
Why?
| | Anemia | 1 | 2016 | 170 | 0.450 |
Why?
| | Lymphoma | 1 | 2016 | 208 | 0.450 |
Why?
| | Bone Marrow | 1 | 2016 | 286 | 0.450 |
Why?
| | Heart Ventricles | 1 | 2019 | 788 | 0.440 |
Why?
| | Thrombocytopenia | 1 | 2016 | 200 | 0.430 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2023 | 437 | 0.430 |
Why?
| | Aged | 14 | 2025 | 23961 | 0.430 |
Why?
| | Anaphylaxis | 2 | 2025 | 105 | 0.420 |
Why?
| | Transplant Recipients | 1 | 2015 | 184 | 0.410 |
Why?
| | Myocardial Contraction | 1 | 2015 | 341 | 0.410 |
Why?
| | Research | 1 | 2016 | 451 | 0.410 |
Why?
| | Environmental Exposure | 1 | 2018 | 579 | 0.410 |
Why?
| | Thrombocytosis | 1 | 2013 | 6 | 0.410 |
Why?
| | Betacoronavirus | 6 | 2020 | 270 | 0.410 |
Why?
| | Lymphoma, Primary Effusion | 1 | 2013 | 4 | 0.400 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2013 | 14 | 0.400 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2023 | 234 | 0.390 |
Why?
| | Antigens, Protozoan | 1 | 2012 | 24 | 0.390 |
Why?
| | Herpesvirus 8, Human | 1 | 2013 | 65 | 0.390 |
Why?
| | Acinetobacter Infections | 1 | 2012 | 14 | 0.390 |
Why?
| | Acinetobacter | 1 | 2012 | 13 | 0.390 |
Why?
| | Proctitis | 1 | 2012 | 7 | 0.380 |
Why?
| | Herpes Genitalis | 1 | 2012 | 16 | 0.380 |
Why?
| | H-2 Antigens | 1 | 2012 | 115 | 0.380 |
Why?
| | Herpesvirus 2, Human | 1 | 2012 | 29 | 0.380 |
Why?
| | Cellulitis | 1 | 2012 | 53 | 0.380 |
Why?
| | Isoxazoles | 1 | 2012 | 54 | 0.370 |
Why?
| | Yellow Fever Vaccine | 2 | 2022 | 6 | 0.370 |
Why?
| | Incidence | 3 | 2025 | 2804 | 0.370 |
Why?
| | Severe Dengue | 1 | 2011 | 10 | 0.370 |
Why?
| | Acyclovir | 1 | 2012 | 101 | 0.370 |
Why?
| | Treatment Outcome | 12 | 2025 | 10811 | 0.360 |
Why?
| | Herpesviridae Infections | 1 | 2013 | 147 | 0.360 |
Why?
| | Emigration and Immigration | 2 | 2022 | 46 | 0.360 |
Why?
| | Animals | 16 | 2025 | 36940 | 0.360 |
Why?
| | Healthcare Disparities | 3 | 2024 | 654 | 0.350 |
Why?
| | Databases, Factual | 3 | 2025 | 1357 | 0.340 |
Why?
| | Poliovirus | 2 | 2022 | 85 | 0.340 |
Why?
| | B-Lymphocytes | 1 | 2016 | 847 | 0.340 |
Why?
| | Pancreatitis | 1 | 2011 | 134 | 0.330 |
Why?
| | Young Adult | 11 | 2025 | 13209 | 0.330 |
Why?
| | Moraxella | 1 | 2009 | 5 | 0.320 |
Why?
| | Moraxellaceae Infections | 1 | 2009 | 3 | 0.320 |
Why?
| | Acute Lung Injury | 1 | 2013 | 287 | 0.320 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3566 | 0.320 |
Why?
| | Lung Diseases | 2 | 2018 | 767 | 0.320 |
Why?
| | Aged, 80 and over | 6 | 2025 | 7635 | 0.320 |
Why?
| | Repressor Proteins | 1 | 2013 | 427 | 0.320 |
Why?
| | Lupus Nephritis | 1 | 2009 | 63 | 0.310 |
Why?
| | Fluconazole | 3 | 2023 | 19 | 0.310 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2531 | 0.310 |
Why?
| | Pulmonary Emphysema | 1 | 2011 | 288 | 0.300 |
Why?
| | Arthritis, Infectious | 1 | 2009 | 69 | 0.300 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 1276 | 0.290 |
Why?
| | Presenilin-1 | 1 | 2008 | 31 | 0.290 |
Why?
| | Fatal Outcome | 2 | 2019 | 303 | 0.290 |
Why?
| | Immunoglobulin G | 3 | 2023 | 893 | 0.280 |
Why?
| | Engineering | 1 | 2018 | 31 | 0.280 |
Why?
| | Staphylococcal Infections | 3 | 2023 | 400 | 0.280 |
Why?
| | Social Responsibility | 1 | 2018 | 51 | 0.280 |
Why?
| | Echinocandins | 2 | 2023 | 7 | 0.270 |
Why?
| | Mycobacterium | 2 | 2018 | 108 | 0.260 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2018 | 98 | 0.260 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1692 | 0.250 |
Why?
| | Public Health | 3 | 2020 | 588 | 0.250 |
Why?
| | Antiviral Agents | 1 | 2012 | 744 | 0.250 |
Why?
| | Attitude | 1 | 2018 | 259 | 0.250 |
Why?
| | HIV | 2 | 2018 | 234 | 0.250 |
Why?
| | Mental Disorders | 2 | 2025 | 1077 | 0.240 |
Why?
| | Tick Bites | 1 | 2025 | 6 | 0.240 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 1050 | 0.240 |
Why?
| | Sepsis | 2 | 2022 | 617 | 0.240 |
Why?
| | Electrocardiography | 2 | 2019 | 629 | 0.240 |
Why?
| | Leprosy, Lepromatous | 1 | 2025 | 5 | 0.240 |
Why?
| | Erythema Nodosum | 1 | 2025 | 8 | 0.240 |
Why?
| | Paresthesia | 1 | 2025 | 15 | 0.230 |
Why?
| | Clarithromycin | 1 | 2025 | 28 | 0.230 |
Why?
| | Erythromycin | 1 | 2025 | 25 | 0.230 |
Why?
| | Candida tropicalis | 1 | 2024 | 4 | 0.230 |
Why?
| | Uveitis, Anterior | 1 | 2025 | 18 | 0.230 |
Why?
| | Propensity Score | 2 | 2023 | 294 | 0.230 |
Why?
| | Shock, Septic | 2 | 2021 | 219 | 0.230 |
Why?
| | Gelatin | 1 | 2025 | 52 | 0.230 |
Why?
| | Acute Kidney Injury | 1 | 2013 | 815 | 0.230 |
Why?
| | Cross Reactions | 1 | 2025 | 133 | 0.230 |
Why?
| | Polymorphism, Genetic | 1 | 2008 | 660 | 0.230 |
Why?
| | Insect Bites and Stings | 1 | 2024 | 12 | 0.230 |
Why?
| | Strongyloides stercoralis | 1 | 2024 | 2 | 0.220 |
Why?
| | Azithromycin | 1 | 2025 | 100 | 0.220 |
Why?
| | Refugees | 1 | 2025 | 75 | 0.220 |
Why?
| | Teicoplanin | 2 | 2023 | 15 | 0.220 |
Why?
| | Colorado | 3 | 2020 | 4565 | 0.220 |
Why?
| | Peru | 2 | 2024 | 58 | 0.210 |
Why?
| | World Health Organization | 2 | 2021 | 123 | 0.210 |
Why?
| | Observational Studies as Topic | 2 | 2025 | 117 | 0.210 |
Why?
| | Meningoencephalitis | 1 | 2023 | 25 | 0.210 |
Why?
| | Toxoplasmosis | 1 | 2023 | 40 | 0.210 |
Why?
| | Toxoplasma | 1 | 2023 | 42 | 0.210 |
Why?
| | Voriconazole | 1 | 2023 | 20 | 0.210 |
Why?
| | Alanine | 1 | 2024 | 152 | 0.210 |
Why?
| | Rabies Vaccines | 1 | 2022 | 3 | 0.200 |
Why?
| | Rabies | 1 | 2022 | 4 | 0.200 |
Why?
| | Georgia | 2 | 2025 | 86 | 0.200 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 2031 | 0.200 |
Why?
| | Glycopeptides | 1 | 2023 | 43 | 0.200 |
Why?
| | Antiparasitic Agents | 1 | 2022 | 3 | 0.200 |
Why?
| | Pyridones | 1 | 2024 | 168 | 0.200 |
Why?
| | Tenofovir | 1 | 2024 | 243 | 0.190 |
Why?
| | Students | 1 | 2018 | 622 | 0.190 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 889 | 0.190 |
Why?
| | Americas | 1 | 2022 | 28 | 0.190 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 1066 | 0.190 |
Why?
| | Sexually Transmitted Diseases | 1 | 2024 | 161 | 0.190 |
Why?
| | Disease Notification | 1 | 2022 | 17 | 0.190 |
Why?
| | Travel Medicine | 2 | 2020 | 5 | 0.190 |
Why?
| | Italy | 1 | 2022 | 110 | 0.190 |
Why?
| | Pregnancy | 4 | 2024 | 6763 | 0.190 |
Why?
| | Dog Diseases | 1 | 2022 | 64 | 0.190 |
Why?
| | Alzheimer Disease | 1 | 2008 | 560 | 0.190 |
Why?
| | Prognosis | 3 | 2022 | 4030 | 0.190 |
Why?
| | Tomography, X-Ray Computed | 4 | 2019 | 2691 | 0.190 |
Why?
| | Staphylococcal Skin Infections | 2 | 2012 | 35 | 0.180 |
Why?
| | Leprosy | 1 | 2021 | 24 | 0.180 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2023 | 230 | 0.180 |
Why?
| | Proportional Hazards Models | 1 | 2024 | 1266 | 0.180 |
Why?
| | Rural Population | 2 | 2022 | 563 | 0.180 |
Why?
| | Population Dynamics | 1 | 2022 | 151 | 0.180 |
Why?
| | Leishmania guyanensis | 1 | 2020 | 1 | 0.170 |
Why?
| | Phosphorylcholine | 1 | 2020 | 20 | 0.170 |
Why?
| | Antiprotozoal Agents | 1 | 2020 | 16 | 0.170 |
Why?
| | Personal Protective Equipment | 1 | 2021 | 52 | 0.170 |
Why?
| | Pericarditis | 1 | 2020 | 10 | 0.170 |
Why?
| | Leishmaniasis, Cutaneous | 1 | 2020 | 14 | 0.170 |
Why?
| | Weight Gain | 1 | 2024 | 519 | 0.170 |
Why?
| | Case-Control Studies | 3 | 2018 | 3556 | 0.170 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 43 | 0.170 |
Why?
| | Anti-Inflammatory Agents | 1 | 2024 | 496 | 0.170 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2022 | 1242 | 0.170 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 36 | 0.160 |
Why?
| | Vaccines | 1 | 2025 | 406 | 0.160 |
Why?
| | Africa | 1 | 2020 | 108 | 0.160 |
Why?
| | Late Onset Disorders | 1 | 2019 | 2 | 0.160 |
Why?
| | Immunization, Secondary | 1 | 2020 | 87 | 0.160 |
Why?
| | Developing Countries | 1 | 2022 | 307 | 0.160 |
Why?
| | Bolivia | 1 | 2019 | 65 | 0.160 |
Why?
| | Proteinuria | 1 | 2020 | 97 | 0.160 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2020 | 70 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 2426 | 0.150 |
Why?
| | Infection Control | 1 | 2021 | 167 | 0.150 |
Why?
| | Invasive Fungal Infections | 1 | 2019 | 11 | 0.150 |
Why?
| | Amphotericin B | 1 | 2019 | 31 | 0.150 |
Why?
| | Medical Errors | 1 | 2020 | 112 | 0.150 |
Why?
| | Cryptococcus gattii | 1 | 2018 | 1 | 0.150 |
Why?
| | Immunosuppressive Agents | 1 | 2024 | 890 | 0.150 |
Why?
| | Vulnerable Populations | 1 | 2020 | 163 | 0.150 |
Why?
| | Sexual and Gender Minorities | 1 | 2022 | 214 | 0.150 |
Why?
| | Acute Disease | 2 | 2012 | 1007 | 0.150 |
Why?
| | Dermatitis | 1 | 2018 | 20 | 0.150 |
Why?
| | Speech Disorders | 1 | 2018 | 31 | 0.150 |
Why?
| | Prospective Studies | 4 | 2023 | 7604 | 0.150 |
Why?
| | Echocardiography | 2 | 2020 | 642 | 0.150 |
Why?
| | Africa, Western | 1 | 2018 | 17 | 0.150 |
Why?
| | Computed Tomography Angiography | 1 | 2019 | 129 | 0.150 |
Why?
| | Stroke Volume | 1 | 2021 | 612 | 0.150 |
Why?
| | Administration, Intravenous | 1 | 2019 | 155 | 0.140 |
Why?
| | Raw Foods | 1 | 2018 | 3 | 0.140 |
Why?
| | Emigrants and Immigrants | 1 | 2020 | 136 | 0.140 |
Why?
| | California | 1 | 2019 | 431 | 0.140 |
Why?
| | Ventricular Function, Left | 1 | 2021 | 534 | 0.140 |
Why?
| | Sex Factors | 1 | 2024 | 2071 | 0.140 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 286 | 0.140 |
Why?
| | Itraconazole | 1 | 2017 | 6 | 0.140 |
Why?
| | Time Factors | 2 | 2019 | 6828 | 0.140 |
Why?
| | Administration, Oral | 2 | 2020 | 816 | 0.140 |
Why?
| | Prisoners | 1 | 2020 | 148 | 0.140 |
Why?
| | Food Microbiology | 1 | 2018 | 66 | 0.140 |
Why?
| | Arrhythmias, Cardiac | 1 | 2020 | 333 | 0.140 |
Why?
| | Neoplasms | 1 | 2013 | 2671 | 0.140 |
Why?
| | Comorbidity | 3 | 2025 | 1622 | 0.140 |
Why?
| | Hyponatremia | 1 | 2018 | 42 | 0.140 |
Why?
| | Respiration, Artificial | 1 | 2022 | 645 | 0.140 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2844 | 0.140 |
Why?
| | Cytokines | 2 | 2022 | 2085 | 0.140 |
Why?
| | Disability Evaluation | 1 | 2019 | 290 | 0.130 |
Why?
| | Farmers | 1 | 2017 | 64 | 0.130 |
Why?
| | Patient Safety | 1 | 2020 | 314 | 0.130 |
Why?
| | Mebendazole | 1 | 2016 | 2 | 0.130 |
Why?
| | Strongyloides | 1 | 2016 | 2 | 0.130 |
Why?
| | Trichuris | 1 | 2016 | 3 | 0.130 |
Why?
| | Arachis | 1 | 2017 | 112 | 0.130 |
Why?
| | Albendazole | 1 | 2016 | 5 | 0.130 |
Why?
| | Research Design | 2 | 2021 | 1139 | 0.130 |
Why?
| | Antibodies, Viral | 1 | 2020 | 625 | 0.130 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 250 | 0.130 |
Why?
| | Ivermectin | 1 | 2016 | 13 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 806 | 0.130 |
Why?
| | Pharmacists | 1 | 2019 | 265 | 0.120 |
Why?
| | Hematocrit | 1 | 2016 | 96 | 0.120 |
Why?
| | Brain | 1 | 2008 | 2668 | 0.120 |
Why?
| | Hospitals, University | 1 | 2016 | 182 | 0.120 |
Why?
| | Praziquantel | 1 | 2015 | 5 | 0.120 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1289 | 0.120 |
Why?
| | Interleukin-6 | 1 | 2020 | 778 | 0.120 |
Why?
| | Vaccination | 2 | 2022 | 1381 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 740 | 0.120 |
Why?
| | Anthelmintics | 1 | 2015 | 11 | 0.120 |
Why?
| | Clone Cells | 1 | 2016 | 265 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1483 | 0.120 |
Why?
| | Disease Outbreaks | 3 | 2023 | 395 | 0.120 |
Why?
| | Genotype | 2 | 2012 | 1916 | 0.120 |
Why?
| | Recurrence | 1 | 2018 | 1060 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2018 | 512 | 0.110 |
Why?
| | Migraine Disorders | 1 | 2016 | 102 | 0.110 |
Why?
| | Health Care Costs | 1 | 2018 | 398 | 0.110 |
Why?
| | Herpesvirus 4, Human | 1 | 2015 | 166 | 0.110 |
Why?
| | Frontal Lobe | 1 | 2015 | 149 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 139 | 0.110 |
Why?
| | Hearing Loss | 1 | 2018 | 221 | 0.110 |
Why?
| | Child | 7 | 2025 | 21935 | 0.110 |
Why?
| | Lipids | 1 | 2019 | 672 | 0.110 |
Why?
| | Biopsy | 2 | 2020 | 1129 | 0.110 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5472 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1509 | 0.110 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 565 | 0.110 |
Why?
| | Hemoglobins | 1 | 2016 | 353 | 0.110 |
Why?
| | Heart Transplantation | 1 | 2020 | 754 | 0.110 |
Why?
| | Vancomycin | 2 | 2025 | 84 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2021 | 951 | 0.100 |
Why?
| | Intensive Care Units | 3 | 2025 | 827 | 0.100 |
Why?
| | Parasite Load | 1 | 2013 | 10 | 0.100 |
Why?
| | Mycoplasma hominis | 1 | 2012 | 4 | 0.100 |
Why?
| | Health Status Disparities | 3 | 2020 | 289 | 0.100 |
Why?
| | Mycoplasma Infections | 1 | 2012 | 16 | 0.100 |
Why?
| | APACHE | 1 | 2013 | 69 | 0.100 |
Why?
| | Intestines | 1 | 2016 | 357 | 0.100 |
Why?
| | Klebsiella Infections | 1 | 2013 | 26 | 0.100 |
Why?
| | Platelet Count | 1 | 2013 | 86 | 0.100 |
Why?
| | Molecular Typing | 1 | 2012 | 22 | 0.100 |
Why?
| | Clindamycin | 1 | 2012 | 15 | 0.100 |
Why?
| | Disease Progression | 2 | 2012 | 2757 | 0.100 |
Why?
| | Syncope | 1 | 2013 | 52 | 0.100 |
Why?
| | Logistic Models | 1 | 2018 | 2074 | 0.100 |
Why?
| | Serratia Infections | 1 | 2012 | 8 | 0.100 |
Why?
| | Serratia marcescens | 1 | 2012 | 16 | 0.100 |
Why?
| | Linkage Disequilibrium | 1 | 2013 | 268 | 0.100 |
Why?
| | Anti-HIV Agents | 2 | 2024 | 778 | 0.100 |
Why?
| | Feces | 1 | 2015 | 484 | 0.100 |
Why?
| | Central America | 2 | 2023 | 24 | 0.100 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2013 | 87 | 0.090 |
Why?
| | Disease Eradication | 2 | 2022 | 4 | 0.090 |
Why?
| | Mice, Inbred BALB C | 1 | 2015 | 1272 | 0.090 |
Why?
| | Thoracic Vertebrae | 1 | 2012 | 77 | 0.090 |
Why?
| | Hedgehog Proteins | 1 | 2013 | 195 | 0.090 |
Why?
| | Viral Load | 2 | 2024 | 466 | 0.090 |
Why?
| | Blister | 1 | 2011 | 41 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2012 | 73 | 0.090 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2011 | 42 | 0.090 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2015 | 528 | 0.090 |
Why?
| | Microscopy | 1 | 2013 | 152 | 0.090 |
Why?
| | Poliovirus Vaccine, Oral | 2 | 2022 | 25 | 0.090 |
Why?
| | Soft Tissue Infections | 1 | 2011 | 37 | 0.090 |
Why?
| | Venezuela | 2 | 2021 | 8 | 0.090 |
Why?
| | Drug Resistance, Viral | 1 | 2012 | 116 | 0.090 |
Why?
| | Drug Resistance, Bacterial | 1 | 2012 | 186 | 0.090 |
Why?
| | Myocardium | 1 | 2016 | 1002 | 0.090 |
Why?
| | Prevalence | 1 | 2018 | 2734 | 0.090 |
Why?
| | Coinfection | 1 | 2012 | 137 | 0.090 |
Why?
| | HIV Seropositivity | 1 | 2011 | 125 | 0.090 |
Why?
| | Gene Expression | 1 | 2015 | 1502 | 0.080 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2013 | 242 | 0.080 |
Why?
| | Cross Infection | 1 | 2013 | 256 | 0.080 |
Why?
| | Cohort Studies | 3 | 2022 | 5742 | 0.080 |
Why?
| | Community-Acquired Infections | 1 | 2012 | 174 | 0.080 |
Why?
| | Penicillanic Acid | 1 | 2009 | 5 | 0.080 |
Why?
| | Piperacillin | 1 | 2009 | 9 | 0.080 |
Why?
| | Urinary Tract Infections | 1 | 2012 | 188 | 0.080 |
Why?
| | Adolescent | 6 | 2025 | 21513 | 0.080 |
Why?
| | Bacterial Typing Techniques | 1 | 2009 | 44 | 0.080 |
Why?
| | Mice | 3 | 2023 | 17787 | 0.080 |
Why?
| | Debridement | 1 | 2009 | 81 | 0.080 |
Why?
| | Surgical Wound Infection | 1 | 2012 | 307 | 0.080 |
Why?
| | Anti-Infective Agents | 1 | 2011 | 255 | 0.070 |
Why?
| | Spinal Cord Injuries | 1 | 2012 | 212 | 0.070 |
Why?
| | Hypertension | 1 | 2018 | 1295 | 0.070 |
Why?
| | Infusions, Intravenous | 1 | 2009 | 413 | 0.070 |
Why?
| | Needs Assessment | 2 | 2021 | 376 | 0.070 |
Why?
| | Genes, Dominant | 1 | 2008 | 96 | 0.070 |
Why?
| | Socialization | 1 | 2018 | 26 | 0.070 |
Why?
| | Mortality | 2 | 2021 | 362 | 0.070 |
Why?
| | Chromosome Disorders | 1 | 2008 | 43 | 0.070 |
Why?
| | Point Mutation | 1 | 2008 | 235 | 0.070 |
Why?
| | Global Health | 2 | 2020 | 386 | 0.070 |
Why?
| | Genetic Markers | 1 | 2008 | 344 | 0.070 |
Why?
| | Amino Acid Substitution | 1 | 2008 | 307 | 0.070 |
Why?
| | DNA Mutational Analysis | 1 | 2008 | 399 | 0.070 |
Why?
| | Pedigree | 1 | 2008 | 514 | 0.070 |
Why?
| | Gene Frequency | 1 | 2008 | 521 | 0.070 |
Why?
| | Chronic Disease | 1 | 2012 | 1793 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 2012 | 758 | 0.060 |
Why?
| | Amyloid beta-Peptides | 1 | 2008 | 220 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 570 | 0.060 |
Why?
| | New York City | 1 | 2025 | 85 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2607 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2189 | 0.060 |
Why?
| | Adenocarcinoma | 1 | 2012 | 940 | 0.060 |
Why?
| | Genetic Testing | 1 | 2008 | 460 | 0.060 |
Why?
| | Interviews as Topic | 1 | 2018 | 786 | 0.060 |
Why?
| | Registries | 1 | 2013 | 2035 | 0.060 |
Why?
| | Antivenins | 1 | 2024 | 36 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 1043 | 0.060 |
Why?
| | Moths | 1 | 2024 | 45 | 0.050 |
Why?
| | Aminobutyrates | 1 | 2024 | 35 | 0.050 |
Why?
| | Drug Substitution | 1 | 2024 | 54 | 0.050 |
Why?
| | Peptide Fragments | 1 | 2008 | 706 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 5757 | 0.050 |
Why?
| | Acetazolamide | 1 | 2023 | 26 | 0.050 |
Why?
| | Antibodies, Protozoan | 1 | 2023 | 36 | 0.050 |
Why?
| | Human Rights | 1 | 2023 | 28 | 0.050 |
Why?
| | Seroepidemiologic Studies | 1 | 2023 | 165 | 0.050 |
Why?
| | HIV Integrase Inhibitors | 1 | 2024 | 70 | 0.050 |
Why?
| | Panama | 1 | 2022 | 13 | 0.050 |
Why?
| | Yellow fever virus | 1 | 2022 | 4 | 0.050 |
Why?
| | Medicine, Traditional | 1 | 2022 | 24 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 147 | 0.050 |
Why?
| | Monkeypox virus | 1 | 2022 | 17 | 0.050 |
Why?
| | Standard of Care | 1 | 2023 | 72 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 1 | 2023 | 269 | 0.050 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 2022 | 28 | 0.050 |
Why?
| | Cell Line | 1 | 2008 | 2847 | 0.050 |
Why?
| | Violence | 1 | 2025 | 266 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2023 | 289 | 0.050 |
Why?
| | Sex Offenses | 1 | 2025 | 196 | 0.050 |
Why?
| | Adenine | 1 | 2024 | 271 | 0.050 |
Why?
| | Mexico | 1 | 2022 | 225 | 0.050 |
Why?
| | Cameroon | 1 | 2021 | 9 | 0.050 |
Why?
| | Cuba | 1 | 2021 | 12 | 0.050 |
Why?
| | Mycobacterium leprae | 1 | 2021 | 8 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2023 | 361 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4295 | 0.050 |
Why?
| | Contact Tracing | 1 | 2021 | 27 | 0.050 |
Why?
| | Healthy Volunteers | 1 | 2022 | 199 | 0.050 |
Why?
| | Dogs | 1 | 2022 | 413 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2022 | 184 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2129 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 5778 | 0.040 |
Why?
| | Curriculum | 1 | 2018 | 992 | 0.040 |
Why?
| | Minority Health | 1 | 2021 | 20 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2025 | 911 | 0.040 |
Why?
| | Cardiovascular Infections | 1 | 2020 | 1 | 0.040 |
Why?
| | Pericardiocentesis | 1 | 2020 | 9 | 0.040 |
Why?
| | History, 17th Century | 1 | 2020 | 16 | 0.040 |
Why?
| | Minority Groups | 1 | 2022 | 266 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 186 | 0.040 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.040 |
Why?
| | Social Justice | 1 | 2021 | 73 | 0.040 |
Why?
| | Inflammation | 2 | 2022 | 2837 | 0.040 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2024 | 394 | 0.040 |
Why?
| | Crowding | 1 | 2020 | 35 | 0.040 |
Why?
| | Hemorrhage | 1 | 2024 | 722 | 0.040 |
Why?
| | Policy Making | 1 | 2020 | 98 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2020 | 82 | 0.040 |
Why?
| | Brazil | 1 | 2020 | 167 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 396 | 0.040 |
Why?
| | Signal Transduction | 1 | 2013 | 5079 | 0.040 |
Why?
| | History, 21st Century | 1 | 2020 | 213 | 0.040 |
Why?
| | Catheter-Related Infections | 1 | 2020 | 92 | 0.040 |
Why?
| | Frail Elderly | 1 | 2020 | 131 | 0.040 |
Why?
| | Cough | 1 | 2020 | 122 | 0.040 |
Why?
| | History, 20th Century | 1 | 2020 | 325 | 0.040 |
Why?
| | Southeastern United States | 1 | 2018 | 32 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2023 | 450 | 0.040 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 322 | 0.040 |
Why?
| | Skilled Nursing Facilities | 1 | 2020 | 141 | 0.040 |
Why?
| | Drug Compounding | 1 | 2019 | 101 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2020 | 197 | 0.040 |
Why?
| | Nursing Homes | 1 | 2020 | 181 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2020 | 236 | 0.040 |
Why?
| | HIV-1 | 1 | 2024 | 864 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2022 | 267 | 0.030 |
Why?
| | Risk | 1 | 2020 | 912 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2020 | 351 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 1062 | 0.030 |
Why?
| | Urban Population | 1 | 2020 | 479 | 0.030 |
Why?
| | Organ Transplantation | 1 | 2020 | 250 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 811 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 691 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 578 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 341 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 804 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3715 | 0.030 |
Why?
| | Mass Screening | 1 | 2022 | 1287 | 0.030 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2012 | 24 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2012 | 68 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3457 | 0.020 |
Why?
| | Infant | 1 | 2021 | 9465 | 0.020 |
Why?
| | Lung | 1 | 2020 | 4060 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2057 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 11074 | 0.020 |
Why?
|
|
Henao Martinez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|